Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Fate Therapeutics Inc's Business Segments
Fate Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Member
Total Revenue
$ 2
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Member0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | $ 3 | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Member0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | $ 3 | - |
Description of Fate Therapeutics Inc
Fate Therapeutics Inc is a biopharmaceutical company that develops advanced cellular therapies that can replace or repair damaged cells in people suffering from severe diseases.
The company is based in San Diego, California, and was founded in 2007.
The company's innovative approach to therapy involves taking cells from a patient's body, engineering them to become specific types of cells, and then reintroducing them into the patient's body, where they can replace or repair damaged cells.
This approach offers a potential solution to many severe diseases, including cancer, genetic disorders, and autoimmune diseases.
Fate Therapeutics Inc's main product is FT516, a treatment designed to replace natural killer cells that work to identify and destroy cancer cells in the body with healthy cells produced outside the body.
They also have other products in development, including FT500, a cancer-killing cell therapy, and FT819, a CAR T-cell therapy for B-cell malignancies.
The company has a strong focus on research and development, and they have partnerships with many leading medical and academic institutions worldwide.
They have also established a strong intellectual property portfolio, which includes over 300 patents and patent applications in the field of cellular therapy.
In summary, Fate Therapeutics Inc is a cutting-edge biopharmaceutical company that develops advanced cellular therapies that can provide a potential cure for many severe diseases.
They have a strong focus on research, development, and intellectual property, making them a leader in the field of cellular therapy.
The company is based in San Diego, California, and was founded in 2007.
The company's innovative approach to therapy involves taking cells from a patient's body, engineering them to become specific types of cells, and then reintroducing them into the patient's body, where they can replace or repair damaged cells.
This approach offers a potential solution to many severe diseases, including cancer, genetic disorders, and autoimmune diseases.
Fate Therapeutics Inc's main product is FT516, a treatment designed to replace natural killer cells that work to identify and destroy cancer cells in the body with healthy cells produced outside the body.
They also have other products in development, including FT500, a cancer-killing cell therapy, and FT819, a CAR T-cell therapy for B-cell malignancies.
The company has a strong focus on research and development, and they have partnerships with many leading medical and academic institutions worldwide.
They have also established a strong intellectual property portfolio, which includes over 300 patents and patent applications in the field of cellular therapy.
In summary, Fate Therapeutics Inc is a cutting-edge biopharmaceutical company that develops advanced cellular therapies that can provide a potential cure for many severe diseases.
They have a strong focus on research, development, and intellectual property, making them a leader in the field of cellular therapy.
Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company that specializes in the development of cellular immunotherapies aimed at treating cancer and immune-related disorders. The company operates within the biotechnology industry and has established itself as a pioneer in the field of engineered cell therapy, focusing on developing universal, off-the-shelf therapy products that can be used broadly in patient populations.
Segments
Fate Therapeutics operates primarily in the following segments:
1. Cellular Immunotherapy Development: This segment is dedicated to creating and advancing novel therapeutic products that leverage the immune system to fight cancer and other diseases.
2. Clinical Research and Trials: This segment focuses on conducting clinical trials to assess the safety and efficacy of its product candidates.
3. Cell Programming Technology: The proprietary technology segment includes innovations that enable the creation of engineered cell therapies designed for versatility and broad application.
4. Partnerships and Collaborations: Fate Therapeutics engages in strategic partnerships with other biotechnology companies, academic institutions, and research organizations to enhance its product development capabilities and expand its market reach.
Products and Services
Fate Therapeutics offers an extensive portfolio of innovative products and services in the cellular immunotherapy landscape.
1. FT500: This is a universal, off-the-shelf natural killer (NK) cell product candidate that aims to provide immediate therapeutic effects to patients, particularly focusing on a one-time silencing therapy for patients suffering from various cancers.
2. FT516: Another universal, off-the-shelf NK cell product candidate designed to target hematologic malignancies as well as solid tumors. It leverages engineered NK cells to boost anti-tumor activity effectively.
3. FT596: This candidate is an advanced universal CAR-NK cell product that incorporates a chimeric antigen receptor to enhance its targeting capacity against both hematologic cancers and solid tumors, providing a versatile fighting chance against diverse malignancies.
4. FT819: This product is an allogeneic CAR-T cell therapy designed to address relapsed and refractory hematologic malignancies. It aims to provide a ready-to-use treatment option that can be administered without delays associated with traditional CAR-T cell therapies.
5. FT-210: A next-generation induced pluripotent stem cell (iPSC) product candidate, FT-210 is positioned to treat rare genetic disorders and degenerative diseases through its potential to generate a human cell type that can ameliorate these conditions effectively.
6. Cell Programming Technology: Fate Therapeutics boasts proprietary technology that facilitates the engineered production of off-the-shelf cellular therapies, aiding in the rapid and seamless deployment of treatments in clinical settings. This technology enhances the scalability and accessibility of cell-based therapies.
Clinical Trial Services: Beyond product development, Fate Therapeutics also offers clinical trial services aimed at advancing cellular immunotherapy products. These services include regulatory support, patient recruitment, and trial management, ensuring robust data collection and compliance with regulatory standards.
Conclusion
Fate Therapeutics Inc. is at the forefront of cellular immunotherapy, operating with a clear vision to develop innovative, off-the-shelf products aimed at treating cancer and immune disorders. The strategic focus on universal products and advanced cell programming technologies positions the company to deliver effective therapies that are not only powerful but also widely available, thereby addressing significant unmet medical needs in oncology and beyond. With a strong emphasis on scientific innovation and clinical development, Fate Therapeutics is poised to make significant contributions to the future of immunotherapy.
Segments
Fate Therapeutics operates primarily in the following segments:
1. Cellular Immunotherapy Development: This segment is dedicated to creating and advancing novel therapeutic products that leverage the immune system to fight cancer and other diseases.
2. Clinical Research and Trials: This segment focuses on conducting clinical trials to assess the safety and efficacy of its product candidates.
3. Cell Programming Technology: The proprietary technology segment includes innovations that enable the creation of engineered cell therapies designed for versatility and broad application.
4. Partnerships and Collaborations: Fate Therapeutics engages in strategic partnerships with other biotechnology companies, academic institutions, and research organizations to enhance its product development capabilities and expand its market reach.
Products and Services
Fate Therapeutics offers an extensive portfolio of innovative products and services in the cellular immunotherapy landscape.
1. FT500: This is a universal, off-the-shelf natural killer (NK) cell product candidate that aims to provide immediate therapeutic effects to patients, particularly focusing on a one-time silencing therapy for patients suffering from various cancers.
2. FT516: Another universal, off-the-shelf NK cell product candidate designed to target hematologic malignancies as well as solid tumors. It leverages engineered NK cells to boost anti-tumor activity effectively.
3. FT596: This candidate is an advanced universal CAR-NK cell product that incorporates a chimeric antigen receptor to enhance its targeting capacity against both hematologic cancers and solid tumors, providing a versatile fighting chance against diverse malignancies.
4. FT819: This product is an allogeneic CAR-T cell therapy designed to address relapsed and refractory hematologic malignancies. It aims to provide a ready-to-use treatment option that can be administered without delays associated with traditional CAR-T cell therapies.
5. FT-210: A next-generation induced pluripotent stem cell (iPSC) product candidate, FT-210 is positioned to treat rare genetic disorders and degenerative diseases through its potential to generate a human cell type that can ameliorate these conditions effectively.
6. Cell Programming Technology: Fate Therapeutics boasts proprietary technology that facilitates the engineered production of off-the-shelf cellular therapies, aiding in the rapid and seamless deployment of treatments in clinical settings. This technology enhances the scalability and accessibility of cell-based therapies.
Clinical Trial Services: Beyond product development, Fate Therapeutics also offers clinical trial services aimed at advancing cellular immunotherapy products. These services include regulatory support, patient recruitment, and trial management, ensuring robust data collection and compliance with regulatory standards.
Conclusion
Fate Therapeutics Inc. is at the forefront of cellular immunotherapy, operating with a clear vision to develop innovative, off-the-shelf products aimed at treating cancer and immune disorders. The strategic focus on universal products and advanced cell programming technologies positions the company to deliver effective therapies that are not only powerful but also widely available, thereby addressing significant unmet medical needs in oncology and beyond. With a strong emphasis on scientific innovation and clinical development, Fate Therapeutics is poised to make significant contributions to the future of immunotherapy.